Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $33 to $45.